# Biotricity Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Biotricity Inc.).

## Overview

Biotricity Inc. develops and commercializes connected cardiac monitoring technologies for physicians, clinics, hospitals, and other diagnostic providers. The company’s core model is to place FDA-cleared devices and software into clinical workflows and earn recurring technology fees based on utilization. Its portfolio includes Bioflux COM, Biocore, and Bioheart, which are aimed at ECG, arrhythmia detection, and continuous heart monitoring use cases. Biotricity has also positioned its Biocore Pro cellular device as a flagship product for broader U.S. commercialization. The company is still in an expansion phase, building sales coverage and market penetration rather than relying on a mature installed base.

## Products & services

• Bioflux COM cardiac monitoring device and software
• Biocore / Biocore Pro ECG and arrhythmia monitoring
• Bioheart direct-to-consumer heart monitor
• Connected Holter monitoring and remote cardiac diagnostics
• Utilization-based recurring technology fee services

- **Cardiac monitoring devices** (55%) — FDA-cleared wearable and connected devices used to capture ECG and arrhythmia data.
- **Monitoring software and analytics** (20%) — Software components that support data capture, transmission, and clinical review.
- **Recurring technology services** (20%) — Utilization-based fees charged for access to the company’s monitoring platform.
- **Consumer heart monitoring** (5%) — Direct-to-consumer monitoring products sold for personal cardiac tracking.

- Bioflux COM cardiac monitoring device and software
- Biocore and Biocore Pro ECG/arrhythmia monitoring devices
- Bioheart direct-to-consumer heart monitor
- Connected Holter monitoring solutions
- Remote cardiac diagnostics and monitoring software
- Utilization-based recurring technology fee services

## Customers

Biotricity sells primarily to clinicians and care delivery organizations that need cardiac monitoring tools for diagnosis and follow-up. Its stated target market includes hospitals, clinics, physicians’ offices, and Independent Diagnostic Testing Facilities (IDTFs), where the company’s devices can be used repeatedly on multiple patients. The company also serves clinically focused repeat users who value connected Holter monitoring and arrhythmia detection workflows. Bioheart extends the addressable market to consumers who want continuous heart monitoring outside a physician-led setting. The business depends on convincing these users to adopt its devices and then use them often enough to support recurring technology fees.

- **Physicians and cardiology practices** (primary) — Buy Bioflux COM and Biocore devices to monitor patients for ECG and arrhythmia events and to support diagnostic workflows.
- **Hospitals and clinics** (primary) — Use connected cardiac monitoring systems to expand diagnostic capacity and improve detection accuracy.
- **Independent Diagnostic Testing Facilities (IDTFs)** (secondary) — Purchase or deploy the company’s monitoring technology for repeated patient testing and recurring service usage.
- **Consumers** (emerging) — Buy Bioheart for personal continuous heart monitoring outside a traditional physician setting.

- Physicians and cardiology practices buying monitoring tools for patient diagnosis
- Hospitals and clinics using ECG and arrhythmia monitoring in care pathways
- Independent Diagnostic Testing Facilities needing repeat-use cardiac devices
- Clinically focused repeat users that generate utilization-based fee revenue
- Consumers seeking direct-to-consumer continuous heart monitoring

## Geography

Biotricity’s commercialization focus is primarily the United States, where it has expanded sales coverage to 31 states. The company manufactures or assembles devices in California, which makes U.S. regulatory compliance and domestic supply continuity especially important. Management has indicated an intention to expand further across the broader U.S. market using an insourcing model. The company also references international markets in its risk disclosures, but the available excerpts do not show meaningful non-U.S. revenue disclosure. Geography matters because the business depends on FDA clearance, state-level sales execution, and a reliable domestic manufacturing and supplier base.

- United States is the core commercialization market
- Sales coverage expanded to 31 U.S. states by December 2022
- Devices are assembled in California
- International markets are contemplated but not yet clearly disclosed as material
- U.S. regulatory and supply-chain execution are central to growth

## Strategy

Biotricity’s strategy is to grow recurring technology fee revenue by placing its devices with clinically focused repeat users and increasing utilization across the installed base. The company is expanding its sales force and geographic footprint to penetrate new markets and deepen adoption in existing ones. It is also broadening its product ecosystem with newer FDA-cleared offerings such as Biocore and Biocore Pro, which target a wider patient population than earlier products. The insourcing model is intended to reduce operating overhead while giving physicians access to the company’s technology in a more efficient distribution structure. In parallel, the company is trying to build brand recognition and clinical credibility in a market where larger competitors have more resources and longer operating histories.

- **Expand U.S. sales coverage** (short-term) — More field coverage is needed to place devices with repeat users and convert clinical demand into recurring revenue.
- **Increase recurring utilization revenue** (medium-term) — The business model depends on repeated device use rather than one-time hardware sales.
- **Broaden product portfolio and addressable market** (medium-term) — Newer cleared products can expand the company beyond narrow monitoring use cases into larger patient populations.

- Expand the sales force to increase market penetration
- Grow recurring technology fee revenue through higher device utilization
- Broaden the installed base across more U.S. states
- Commercialize newer products such as Biocore Pro
- Use an insourcing model to lower overhead and improve distribution efficiency
- Target broader clinical use cases and lower-risk patient segments

## Risks

Biotricity faces execution risk because its growth depends on a relatively small sales force, limited operating history, and the ability to win adoption against larger medical device competitors. Regulatory risk is significant because the company’s devices and manufacturing operations must maintain FDA clearance and quality-system compliance, and any lapse could interrupt commercialization. Supply-chain concentration is another issue, since the company relies on a limited number of component suppliers and qualifying replacements can take time. The business is also exposed to pandemic, natural disaster, and broader macro disruptions that can affect facilities, customers, and manufacturing continuity. More generally, the cardiac monitoring market is competitive and technology-driven, so product performance, clinical acceptance, and reimbursement or adoption dynamics can materially affect demand.

- **Competitive pressure from larger medical device companies** [high] — Rivals may have longer operating histories, stronger brand recognition, and greater financial and technical resources, making customer acquisition harder.
- **FDA and manufacturing compliance risk** [high] — The company must maintain regulatory approval for devices and manufacturing facilities; failure could halt commercialization or shipments.
- **Supplier concentration and component shortages** [high] — A limited number of suppliers could delay production or prevent timely delivery if volumes or pricing become unfavorable.
- **Limited operating history** [medium] — Investors have limited evidence on scalability, profitability, and long-term customer retention.
- **Operational disruption from pandemics or natural disasters** [medium] — Facility access, customer access, and supply chains can be interrupted, reducing demand and increasing costs.

- Limited operating history makes future performance hard to evaluate
- Competition from larger medical device companies with more resources
- FDA and manufacturing compliance risk could interrupt sales
- Dependence on a limited number of suppliers can constrain device availability
- Pandemics, natural disasters, and other disruptions can affect operations
- International expansion adds foreign currency, political, and staffing risk

## Accounting

Biotricity recognizes revenue under ASC 606 when promised goods or services are transferred to customers, which is important because its model includes both device-related revenue and recurring service fees. Investors should pay attention to the timing of revenue recognition across hardware, software, and utilization-based services, since these streams may be recognized differently depending on contract terms and performance obligations. The company also discloses significant estimates in share-based compensation, impairment analysis, and the fair value of warrants, structured notes, convertible debt, and conversion liabilities, all of which can materially affect reported earnings and balance sheet values. Because the company is still scaling, quarter-to-quarter results may be volatile as sales force expansion, device placements, and utilization levels move unevenly. These judgments make non-cash expenses and valuation assumptions especially important when comparing reported results across periods.

- **Revenue recognition under ASC 606** — Can shift revenue between periods and affect comparability.
- **Fair value of warrants and convertible debt** — Can materially affect net income and equity.
- **Share-based compensation** — Can significantly increase operating expenses.
- **Impairment analysis** — Could lead to write-downs of assets or intangibles.

- ASC 606 revenue recognition affects timing of device and service revenue
- Utilization-based fees may create uneven quarterly revenue patterns
- Share-based compensation can materially affect operating expenses
- Fair value of warrants and convertible instruments can move earnings
- Impairment analysis may affect asset carrying values
- Estimates and assumptions are important because the company is early in commercialization

---

*Last updated: 2026-08-11T04:46:22.696777+00:00*